Cargando…
Importance of Comprehensive Molecular Profiling for Clinical Outcome in Children With Recurrent Cancer
Purpose: Pediatric cancers are often difficult to classify and can be complex to treat. To ensure precise diagnostics and identify relevant treatment targets, we implemented comprehensive molecular profiling of consecutive pediatric patients with cancer relapse. We evaluated the clinical impact of e...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920151/ https://www.ncbi.nlm.nih.gov/pubmed/29732366 http://dx.doi.org/10.3389/fped.2018.00114 |
_version_ | 1783317777928421376 |
---|---|
author | Østrup, Olga Nysom, Karsten Scheie, David Schmidt, Ane Y. Mathiasen, Rene Hjalgrim, Lisa L. Olsen, Tina E. Skjøth-Rasmussen, Jane Henriksen, Birthe M. Nielsen, Finn C. Wehner, Peder S. Schrøder, Henrik Sehested, Astrid M. Rechnitzer, Catherine Rossing, Maria |
author_facet | Østrup, Olga Nysom, Karsten Scheie, David Schmidt, Ane Y. Mathiasen, Rene Hjalgrim, Lisa L. Olsen, Tina E. Skjøth-Rasmussen, Jane Henriksen, Birthe M. Nielsen, Finn C. Wehner, Peder S. Schrøder, Henrik Sehested, Astrid M. Rechnitzer, Catherine Rossing, Maria |
author_sort | Østrup, Olga |
collection | PubMed |
description | Purpose: Pediatric cancers are often difficult to classify and can be complex to treat. To ensure precise diagnostics and identify relevant treatment targets, we implemented comprehensive molecular profiling of consecutive pediatric patients with cancer relapse. We evaluated the clinical impact of extensive molecular profiling by assessing the frequency of identified biological onco-drivers, altered diagnosis, and/or identification of new relevant targeted therapies. Patients and Methods: Forty-six tumor samples (44 fresh-frozen; two formalin-fixed paraffin embedded), two bone marrow aspirates, three cerebrospinal fluid samples, and one archived DNA were obtained from 48 children (0–17 years; median 9.5) with relapsed or refractory cancer, where the disease was rapidly progressing in spite of their current treatment or they had exhausted all treatment options. The samples were analyzed by whole-exome sequencing (WES), RNA sequencing (RNAseq), transcriptome arrays, and SNP arrays. Final reports were available within 3–4 weeks after patient inclusion and included mutation status, a description of copy number alterations, differentially expressed genes, and gene fusions, as well as suggestions for targeted treatment. Results: Of the 48 patients, 33 had actionable findings. The most efficient method for the identification of actionable findings was WES (39%), followed by SNP array (37%). Of note, gene fusions were identified by RNAseq in 21% of the samples. Eleven findings led to clinical intervention, i.e., oncogenetic counseling, targeted treatment, and treatment based on changed diagnosis. Four patients received compassionate use targeted therapy. Six patients experienced direct benefits in the form of stable disease or response. Conclusion: The application of comprehensive genetic diagnostics in children with recurrent cancers allowed for discovery and implementation of effective targeted therapies and hereby improvement of outcome in some patients. |
format | Online Article Text |
id | pubmed-5920151 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-59201512018-05-04 Importance of Comprehensive Molecular Profiling for Clinical Outcome in Children With Recurrent Cancer Østrup, Olga Nysom, Karsten Scheie, David Schmidt, Ane Y. Mathiasen, Rene Hjalgrim, Lisa L. Olsen, Tina E. Skjøth-Rasmussen, Jane Henriksen, Birthe M. Nielsen, Finn C. Wehner, Peder S. Schrøder, Henrik Sehested, Astrid M. Rechnitzer, Catherine Rossing, Maria Front Pediatr Pediatrics Purpose: Pediatric cancers are often difficult to classify and can be complex to treat. To ensure precise diagnostics and identify relevant treatment targets, we implemented comprehensive molecular profiling of consecutive pediatric patients with cancer relapse. We evaluated the clinical impact of extensive molecular profiling by assessing the frequency of identified biological onco-drivers, altered diagnosis, and/or identification of new relevant targeted therapies. Patients and Methods: Forty-six tumor samples (44 fresh-frozen; two formalin-fixed paraffin embedded), two bone marrow aspirates, three cerebrospinal fluid samples, and one archived DNA were obtained from 48 children (0–17 years; median 9.5) with relapsed or refractory cancer, where the disease was rapidly progressing in spite of their current treatment or they had exhausted all treatment options. The samples were analyzed by whole-exome sequencing (WES), RNA sequencing (RNAseq), transcriptome arrays, and SNP arrays. Final reports were available within 3–4 weeks after patient inclusion and included mutation status, a description of copy number alterations, differentially expressed genes, and gene fusions, as well as suggestions for targeted treatment. Results: Of the 48 patients, 33 had actionable findings. The most efficient method for the identification of actionable findings was WES (39%), followed by SNP array (37%). Of note, gene fusions were identified by RNAseq in 21% of the samples. Eleven findings led to clinical intervention, i.e., oncogenetic counseling, targeted treatment, and treatment based on changed diagnosis. Four patients received compassionate use targeted therapy. Six patients experienced direct benefits in the form of stable disease or response. Conclusion: The application of comprehensive genetic diagnostics in children with recurrent cancers allowed for discovery and implementation of effective targeted therapies and hereby improvement of outcome in some patients. Frontiers Media S.A. 2018-04-20 /pmc/articles/PMC5920151/ /pubmed/29732366 http://dx.doi.org/10.3389/fped.2018.00114 Text en Copyright © 2018 Østrup, Nysom, Scheie, Schmidt, Mathiasen, Hjalgrim, Olsen, Skjøth-Rasmussen, Henriksen, Nielsen, Wehner, Schrøder, Sehested, Rechnitzer and Rossing. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pediatrics Østrup, Olga Nysom, Karsten Scheie, David Schmidt, Ane Y. Mathiasen, Rene Hjalgrim, Lisa L. Olsen, Tina E. Skjøth-Rasmussen, Jane Henriksen, Birthe M. Nielsen, Finn C. Wehner, Peder S. Schrøder, Henrik Sehested, Astrid M. Rechnitzer, Catherine Rossing, Maria Importance of Comprehensive Molecular Profiling for Clinical Outcome in Children With Recurrent Cancer |
title | Importance of Comprehensive Molecular Profiling for Clinical Outcome in Children With Recurrent Cancer |
title_full | Importance of Comprehensive Molecular Profiling for Clinical Outcome in Children With Recurrent Cancer |
title_fullStr | Importance of Comprehensive Molecular Profiling for Clinical Outcome in Children With Recurrent Cancer |
title_full_unstemmed | Importance of Comprehensive Molecular Profiling for Clinical Outcome in Children With Recurrent Cancer |
title_short | Importance of Comprehensive Molecular Profiling for Clinical Outcome in Children With Recurrent Cancer |
title_sort | importance of comprehensive molecular profiling for clinical outcome in children with recurrent cancer |
topic | Pediatrics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5920151/ https://www.ncbi.nlm.nih.gov/pubmed/29732366 http://dx.doi.org/10.3389/fped.2018.00114 |
work_keys_str_mv | AT østrupolga importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer AT nysomkarsten importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer AT scheiedavid importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer AT schmidtaney importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer AT mathiasenrene importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer AT hjalgrimlisal importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer AT olsentinae importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer AT skjøthrasmussenjane importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer AT henriksenbirthem importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer AT nielsenfinnc importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer AT wehnerpeders importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer AT schrøderhenrik importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer AT sehestedastridm importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer AT rechnitzercatherine importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer AT rossingmaria importanceofcomprehensivemolecularprofilingforclinicaloutcomeinchildrenwithrecurrentcancer |